STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
DelistingMay 1, 2026, 04:07 PM

Curis Receives Nasdaq Delisting Notice for Bid Price Rule Violation

AI Summary

Curis, Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, due to its common stock trading below the minimum $1.00 bid price requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company's securities are scheduled for delisting and suspension from the Nasdaq Capital Market on May 6, 2026, unless it timely appeals the decision. Curis plans to request a hearing, which will stay delisting actions, but there's no assurance of a successful appeal or continued listing.

Key Highlights

  • Curis received a Delist Determination Letter from Nasdaq on April 27, 2026.
  • Common stock bid price closed below $1.00 for 30 consecutive business days.
  • Violates Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.
  • Securities scheduled for delisting and suspension on May 6, 2026.
  • Company intends to appeal the delisting determination by May 4, 2026.
  • Appeal will stay further delisting actions, but success is not assured.
  • Company was under a Discretionary Panel Monitor since February 3, 2026.
CRIS
Biotechnology: Biological Products (No Diagnostic Substances)
CURIS INC

Price Impact